Zura Bio Limited (ZURA) Cash Flow Statement

The persistent gap where operating cash flow is more negative than net income suggests that non-cash items like stock-based compensation are not fully offsetting the cash outflows from operations. This pattern, seen in 8 of the last 10 quarters, implies the company's core operational activities are consuming cash at a rate faster than the net loss alone would indicate, a critical dynamic for a pre-revenue firm.

The FCF trajectory shows a clear and concerning acceleration in cash consumption, with the deficit more than doubling over the past two years. This trend is driven by rising operating losses, as capital expenditures remain negligible, confirming that the burn is almost entirely operational. Investors should monitor this trajectory closely for signs of stabilization or further acceleration.

The lack of a consistent pattern in working capital movements is notable for a pre-revenue company. The large positive swing in 2026Q2 provided a temporary cushion to operating cash flow, but the volatility indicates that these movements are not a reliable source of cash and may reflect timing of payments or accruals rather than operational efficiency.

The absence of shareholder returns or strategic acquisitions is expected for a clinical-stage biotech. The only notable deployment was a minor $34K share repurchase in 2025Q2. This conservative posture focuses all available capital on R&D, but it also means the company's value is entirely dependent on the success of its pipeline, with no financial engineering to support the stock.